| Selvita becomes the strategic investor in BioCentrum |
|
Selvita and BioCentrum - both product and solution providers to the pharmaceutical and biotechnology industry have entered into a strategic cooperation agreement. As part of the agreement BioCentrum will become a part of Selvita group and will concentrate the potential of both companies in the area of ADMET contract research, including microbiology and biochemistry assays and the development and production of proteins. Selvita will continue to develop its innovative compound pipeline as well as offer advanced services to the drug industry including drug discovery and design, bioinformatics and chemical informatics.
"The cooperation with Selvita will help us to develop our service offerings, increase research and marketing budgets and increase and improve BioCentrum's laboratory infrastructure", said Prof. Adam Dubin, the founder and former CEO of BioCentrum. "In four years since the company was founded our company has gained a good reputation in the international biotechnology community. Based on our cooperation with the Biochemistry, Biophysics and Biotechnology Department of the Jagiellonian University we developed unique research capabilities and now it is time to reach out for new customers". Selvita acquired 64% of shares of BioCentrum after the capital increase. Pawel Przewiezlikowski, the CEO of Selvita will become also the CEO of BioCentrum, and Boguslaw Sieczkowski, Selvita's Vice President and board member will become a member of the management board of BioCentrum. Professor Adam Dubin, will remain a board member of the company and will assist Selvita in its own research projects. He will assume the role of the President of Selvita?s Scientific Advisory Board which includes seven eminent biomedical research scientists. "BioCentrum has achieved a remarkable success over the last years. The company gained trust of many large and medium-size pharmaceutical and biotechnology companies from Germany, Switzerland, Sweden, USA and Poland. It is already profitable and the revenues are growing dynamically", said Boguslaw Sieczkowski. "Selvita's investment in BioCentrum will create many synergies in customer care, research and infrastructure, and both companies will be able to offer better services to their clients". About BioCentrum BioCentrum is a privately-owned biotechnology service and product provider. The company started in 2004 as a spin-off from the Biochemistry, Biophysics and Biotechnology Department of the Jagiellonian University in Krakow, Poland. The company conducts its own research, development and implementation projects in the area of microbiology, with special focus on bacterial virulence factors as potential therapeutic targets for drug development and antibacterial peptides exerting an antibiotic activity. The company performs also contract research and production of new mouse monoclonal antibodies on a laboratory scale. BioCentrum carries out sequencing and amino acid composition analysis of protein samples, 2D electrophoresis and protein purification. The company possesses a unique expertise and experience in production of highly purified, active enzymes, inhibitors and other biologically active recombinant proteins.BioCentrum enjoys a good cooperation with the Jagiellonian University and is the co-owner of two biotechnology patent applications. More about BioCentrum: http://www.biocentrum.com.pl About SelvitaSelvita is a Polish biotechnology company, founded In 2007 in Krakow, Poland with the aim of helping global pharmaceutical and biotechnology companies to gain efficient access to innovative compounds developed at Polish universities and good research capabilities of Polish scientists. It employs an experienced team of specialists with molecular biology, biotechnology, chemistry, pharmacy, and informatics degrees including 9 PhDs from leading US, German, Swedish, Swiss, Dutch and Polish universities.The company develops its own innovative compounds pipeline up to the IND stage, provides bioinformatics and chemical informatics services to the pharmaceutical industry and pre-clinical research services. More about Selvita: http://www.selvita.com Media contact:BioCentrum:prof. dr. hab. Adam Dubin, Vice President Tel.: +48 12 664 65 06 e-mail: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it Selvita: Boguslaw Sieczkowski, Vice President Tel: +48 12 410 73 80 e-mail: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it |